Osteoclasts are the only somatic cells with bone-resorbing capacity and, as such, they have a critical role not only in normal bone homeostasis (called 'bone remodelling') but also in the pathogenesis of bone destructive disorders such as rheumatoid arthritis and osteoporosis 1 . A major focus of research in the field has been on gene regulation by osteoclastogenic cytokines such as receptor activator of NF-kB-ligand (RANKL, also known as TNFSF11) and TNF-a, both of which have been well documented to contribute to osteoclast terminal differentiation 2, 3 . A crucial process that has been less well studied is the trafficking of osteoclast precursors to and from the bone surface, where they undergo cell fusion to form the fully differentiated multinucleated cells that mediate bone resorption. Here we report that sphingosine-1-phosphate (S1P), a lipid mediator enriched in blood 4,5 , induces chemotaxis and regulates the migration of osteoclast precursors not only in culture but also in vivo, contributing to the dynamic control of bone mineral homeostasis. Cells with the properties of osteoclast precursors express functional S1P 1 receptors and exhibit positive chemotaxis along an S1P gradient in vitro. Intravital two-photon imaging of bone tissues showed that a potent S1P 1 agonist, SEW2871, stimulated motility of osteoclast precursor-containing monocytoid populations in vivo. Osteoclast/monocyte (CD11b, also known as ITGAM) lineage-specific conditional S1P 1 knockout mice showed osteoporotic changes due to increased osteoclast attachment to the bone surface. Furthermore, treatment with the S1P 1 agonist FTY720 relieved ovariectomy-induced osteoporosis in mice by reducing the number of mature osteoclasts attached to the bone surface. Together, these data provide evidence that S1P controls the migratory behaviour of osteoclast precursors, dynamically regulating bone mineral homeostasis, and identifies a critical control point in osteoclastogenesis that may have potential as a therapeutic target.
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Osteoclasts are the only somatic cells with bone-resorbing capacity and, as such, they have a critical role not only in normal bone homeostasis (called 'bone remodelling') but also in the pathogenesis of bone destructive disorders such as rheumatoid arthritis and osteoporosis 1 . A major focus of research in the field has been on gene regulation by osteoclastogenic cytokines such as receptor activator of NF-kB-ligand (RANKL, also known as TNFSF11) and TNF-a, both of which have been well documented to contribute to osteoclast terminal differentiation 2, 3 . A crucial process that has been less well studied is the trafficking of osteoclast precursors to and from the bone surface, where they undergo cell fusion to form the fully differentiated multinucleated cells that mediate bone resorption. Here we report that sphingosine-1-phosphate (S1P), a lipid mediator enriched in blood 4, 5 , induces chemotaxis and regulates the migration of osteoclast precursors not only in culture but also in vivo, contributing to the dynamic control of bone mineral homeostasis. Cells with the properties of osteoclast precursors express functional S1P 1 receptors and exhibit positive chemotaxis along an S1P gradient in vitro. Intravital two-photon imaging of bone tissues showed that a potent S1P 1 agonist, SEW2871, stimulated motility of osteoclast precursor-containing monocytoid populations in vivo. Osteoclast/monocyte (CD11b, also known as ITGAM) lineage-specific conditional S1P 1 knockout mice showed osteoporotic changes due to increased osteoclast attachment to the bone surface. Furthermore, treatment with the S1P 1 agonist FTY720 relieved ovariectomy-induced osteoporosis in mice by reducing the number of mature osteoclasts attached to the bone surface. Together, these data provide evidence that S1P controls the migratory behaviour of osteoclast precursors, dynamically regulating bone mineral homeostasis, and identifies a critical control point in osteoclastogenesis that may have potential as a therapeutic target.
Because of its role in controlling cell migration in other tissues, we initially focused on S1P and the S1P family of receptors (previously known as EDG receptors) responsive to this lipid mediator. The murine monocyte cell line RAW264.7, and mouse bone-marrowderived M-CSF (colony stimulating factor-1, also known as CSF1)-dependent monocytes (termed BM-MDM), which can both differentiate into osteoclast-like cells on exposure to RANKL and represent widely used in vitro models of osteoclast precursors, each express messenger RNAs encoding two receptors for S1P (S1P 1 and S1P 2 , encoded by S1PR1 and S1PR2, respectively.). The expression of S1PR1 mRNA decreased after RANKL stimulation (Fig. 1a, b) , and this transcriptional repression was dependent on NF-kB (blocked by BAY11-7085) but not on NF-AT (also known as NFATC1; blocked by cyclosporin A) (Fig. 1b) , both of which have been recognized as crucial transcriptional factors for osteoclastogenesis [1] [2] [3] . S1P 1 protein expression, as detected by immunocytochemistry, was also reduced by RANKL stimulation (Fig. 1c) . In accord with these in vitro findings, strong immunoreactivity for S1P 1 could be detected in mononuclear cells in native bone tissues (Fig. 1d, arrowheads) , whereas weaker staining was seen in large cells lining bone trabeculae (Fig. 1d , asterisks) that are probably mature osteoclasts (mean fluorescence intensities: 49.1 6 5.8 and 19.4 6 2.0 in mononuclear cells and attached cells, respectively; P 5 0.0003). Both RAW264.7 ( Fig. 1f) and BM-MDM (data not shown) cells showed positive chemotactic responses to an S1P gradient in vitro, and these responses were greatly attenuated by pretreatment with RANKL (Fig. 1f) . This latter finding is concordant with the RANKL-dependent reduction in S1PR1 gene expression (Fig. 1a) . S1P-directed chemotaxis was blocked by pertussis toxin (PTX) 6 and NSC23766 (ref. 7) (Fig. 1f) , and S1P induced an increase in the GTP-bound, active form of Rac (GTPRac) (Fig. 1e) , suggesting that Rac and the adenylyl-cyclaseinhibiting G protein Ga i are involved in the S1P 1 chemotactic signalling pathway in these cells, consistent with previous reports 8, 9 . In vitro chemotaxis of RAW264.7 was also examined using a dynamic imaging approach, in which cells could be observed vigorously migrating towards S1P-containing medium ( Fig. 1g and Supplementary Videos 1 and 2). We also detected S1P-induced upregulation of integrins expressed in monocytoid cells, suggesting that S1P-mediated alterations in cell adhesion could contribute to chemotaxis in vivo ( Supplementary Fig. 1 ).
To investigate whether osteoclast precursor migration is affected by S1P gradients in vivo, we performed intravital two-photon imaging of calvaria bone tissues 10, 11 and examined the migratory behaviour of monocytoid cells containing osteoclast precursors resident in the marrow spaces. We used two strains of mice expressing enhanced green fluorescent protein (EGFP) in subsets of myeloid cells: CX 3 CR1-EGFP knock-in (heterozygous) mice 12, 13 and CSF1R-EGFP transgenic mice 14 . In both strains, haematopoietic monocytelineage cell types predominantly expressed EGFP 12,13 and we confirmed that tartrate-resistant acid phosphatase (TRAP)-positive mature osteoclasts expressed EGFP in these animals (Supplementary Fig. 2 ), a selective agonist for the S1P 1 receptor (Fig. 2a , lower panels, and Supplementary Video 4), with some of the mobilized cells entering the blood circulation (data not shown). A similar but less pronounced effect of SEW2871 on myeloid cell motility was observed in the bone marrow of CSF1R-EGFP transgenic mice (Supplementary Fig. 3 and Supplementary Videos 5 and 6). The difference in the fraction of cells mobilized by SEW2871 treatment in the two mouse strains is probably due to the fact that the EGFPexpressing subsets in these animals are not completely overlapping (Supplementary Table 1 ). Consistent with these findings, we also observed an increase in the percentage and absolute number of monocytoid cells in peripheral blood, and their reciprocal decrease in bone marrow but not spleen or liver, after SEW2871 treatment as compared to vehicle controls ( Supplementary Fig. 4 and Supplementary Table 2 ). These results suggest that bone-marrowresident monocytes, including many osteoclast precursors, become motile and exit marrow spaces in response to S1P stimulation.
To evaluate the in vivo effect of S1P-directed chemotaxis of osteoclast precursors on bone homeostasis, we examined mice deficient in S1P 1 . Because S1P 1 deficiency causes embryonic lethality 17 , we generated osteoclast/monocyte-specific S1P 1 -deficient (S1PR1 2/2 ) mice by crossing animals bearing conditional S1P 1 knockout alleles (S1PR1 loxP ) 18 to transgenic mice expressing Cre under the CD11b promoter 19 , which facilitates deletion of loxP-flanked sequences in monocyte-lineage myeloid cells including osteoclasts. S1PR1 ( Supplementary Fig. 5a, b) and immunoreactivity for S1P 1 was greatly diminished in S1PR1 2/2 bone tissues (Supplementary Fig. 5c ), indicating that there was almost complete ablation of S1P 1 expression in this lineage.
Morphohistometric analyses using micro-CT (mCT) showed that femora of mice genotyped as S1PR1 loxP/loxP CD11b-Cre (S1PR1 2/2 ) were osteoporotic, compared with those of control (S1PR1 1/1 CD11b-Cre) littermates (Fig. 3a, upper panels) . Bone tissue density (bone volume/total volume) of S1PR1 2/2 mice was significantly lower than that of controls (Fig. 3b) , and both trabecular thickness and trabecular density were decreased in S1PR1 2/2 bones (Fig. 3c) . Mice genotyped as S1PR1 loxP/1 CD11b-Cre (heterozygous) were indistinguishable from controls, indicating that a single S1PR1 allele is sufficient to sustain normal S1P 1 -mediated functions.
Bone surface attachment of mature osteoclasts was evaluated by immunohistological examination. Both osteoclasts and bone matrices were visualized simultaneously by fluorescence-based staining for TRAP 20 and by collagen-derived second harmonic signals elicited by two-photon excitation 21 , respectively (Supplementary Fig. 6 ). Images were automatically segmented off-line using a custom software package (F.K., submitted manuscript). An 'osteoclast attachment ratio' (bone surface occupied by osteoclasts/total bone surface) was calculated automatically without manual intervention (Fig. 3a , lower panels and Supplementary Fig. 6 ). The computational analyses showed that osteoclast attachment to the bone surface was significantly enhanced in S1PR1 2/2 animals, as compared to controls (Fig. 3d) , consistent with the decrease in bone density in S1PR1 2/2 mice (Fig. 3b, c) . Because S1P has no measurable effect on in vitro osteoclast differentiation stimulated by RANKL ( Supplementary  Fig. 7 ), a reasonable interpretation of these data are that the loss of S1P 1 function alters the chemotactic behaviour of osteoclast precursors rather than their terminal maturation to osteoclasts or the boneresorbing action of osteoclasts.
Because the concentration of S1P in blood is higher than in tissues, S1P-mediated chemotaxis of osteoclast precursors would thus be expected to contribute to their recirculation from bone tissues to systemic blood flow, limiting formation of mature osteoclasts and reducing bone destruction. The present result showing the increased deposition of S1PR1 2/2 osteoclasts on the bone surface strongly supports the concept of S1P-driven precursor recirculation. It has already been reported that osteoclast precursor monocytes (RAW264.7) show positive chemotaxis in vitro towards CXCL12 (also known as SDF-1), a chemokine secreted from bone marrow stromal cells 22 , leading to a straightforward competitive model for the migration and positioning of osteoclasts (Supplementary Fig. 8 ).
Monocyte-lineage osteoclast precursors come close to the bone surface attracted by CXCL12, however not all of the recruited cells undergo differentiation, and some of the precursors recirculate into the blood flow owing to attraction by S1P. Some osteoclast precursors may be directly derived within bone marrow spaces ( Supplementary Fig. 8, dashed arrow) , and they are also susceptible to S1P-driven 'circulation' into the systemic flow. During osteoclast differentiation induced by RANKL, the expression of S1P 1 is repressed (Fig. 1a) which ensures stable localization of the maturing cells on the bone surface. Regulation of osteoclast generation by competing chemokine pathways that attract precursors to and from the bone surface allows finely-tuned dynamic control of osteoclastogenesis during health and in various conditions such as inflammation and metabolic disorders. Bone surface CXCL12 expression has recently been shown to be regulated by sympathetic neuron stimulation 23 , suggesting that there is an interesting interaction between circulating S1P and the autonomic nervous system for the regulation of osteoclast precursor mobilization.
This newly revealed role of S1P-directed recirculation of osteoclast precursor in bone homeostasis prompted us to examine possible therapeutic implications of this regulatory pathway. FTY720 (Fingolimod) is metabolized after administration to an agonist for four of the five S1P receptors, including S1P 1 (but not S1P 2 ), and has emerged as a clinically promising immunosuppressive drug 24, 25 that presumably acts by limiting effector lymphocyte egress from lymph nodes. FTY720 is at present being tested clinically in multiple sclerosis and allogeneic transplantation 26, 27 , but has not been examined for its effect on bone homeostasis. Here we show that FTY720 has a capacity to ameliorate bone loss in a model of postmenopausal osteoporosis.
Either ovariectomized or sham-operated mice were administered FTY720 (3 mg kg 21 day
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) for 4 weeks after which excised femora were analysed by mCT (Fig. 4a, b) . FTY720 treatment significantly prevented bone density loss after ovariectomy, but had no effects under control (sham-operated) conditions. Computational morphometrical analyses showed that osteoclast attachment was increased after ovariectomy and partially restored to normal levels by FTY720 administration. We confirmed that FTY720 had no effect on oestrogen levels after ovariectomy (Supplementary Table 3 ). These results indicate that FTY720 relieves ovariectomy-induced bone loss by reducing osteoclast deposition onto bone surfaces. This effect correlated with an increase in circulating CX 3 CR1-EGFP 1 F4/80 1 (Fig. 4c) and CD11b 1 monocytes ( Supplementary Fig. 9 ), both of which populations include osteoclast precursors, and a concomitant decrease in monocytoid cells including osteoclast precursors in the bone marrow ( Supplementary  Fig. 9 and Supplementary Table 2 ). In addition, intravital two-photon imaging showed that FTY720 significantly stimulated motility of CX 3 CR1-EGFP 1 monocyte-lineage cells (Fig. 4d and Supplementary Video 7). The short-term mobility change seen using FTY720 (as observed by intravital microscopy) was less prominent than that obtained with SEW2871 (Fig. 2) . This difference may arise because SEW2871 is active after intravenous injection, whereas FTY720 needs to be metabolized (phosphorylated) before becoming functional ( Supplementary Fig. 10 ). We cannot rule out, however, the possibility that phospho-FTY720 can activate S1P receptors other than S1P 1 that are expressed on other cell types, such as endothelial cells. FTY720 was shown to have no effects on the expression of RANKL or osteoprotegerin (data not shown). Taken together, these results (S1PR1 loxP/loxP CD11b-Cre) littermates. Femoral bone samples were analysed by cone-beam mCT (top panels) and by histological examination combined with computational quantification for measuring the osteoclast attachment ratio to the bone surface (bottom panels; see also Supplementary indicate that FTY720, a potent S1P 1 agonist, promotes the recirculation of osteoclast precursor monocytes from bone surface, an effect that counteracts ovariectomy-induced augmentation of osteoclastogenesis. This agonist effect of FTY720 on myeloid cells directly accessible to the blood circulation differs from the consequence of lymphocyte S1P 1 engagement by phosphorylated FTY720 within secondary lymphoid tissues, in which case downmodulation of the receptor results in functional antagonism of this pathway.
The present study provides evidence that S1P, as a circulationattraction molecule, controls the migratory behaviour of osteoclast precursors, dynamically regulating bone mineral homeostasis in collaboration with bone-attraction molecules, such as CXCL12, and identifies a critical control point in osteoclastogenesis that has potential as a therapeutic target.
METHODS SUMMARY
The RAW264.7 cell line and mouse BM-MDM cells, which contains osteoclast precursor cells, were cultured and stimulated to differentiate using RANKL as previously described 28, 29 . In vitro chemotactic activity was evaluated using a modified Boyden's chamber 30 or with a visually-accessible chemotactic chamber, EZ-Taxiscan. In vivo S1P-directed chemotaxis of osteoclast precursor monocytes was visualized by intravital two-photon microscopy of mouse calvaria bone tissues of heterozygous CX 3 CR1-EGFP knock-in mice 12 and of CSF1R-EGFP transgenic 14 mice, according to a protocol modified from a previous report 10, 11 . The generation of the loxP-flanked S1PR1 allele (S1PR1 loxP ) 18 and osteoclast/ monocyte lineage-specific CD11b-Cre transgenic mice 19 have been described previously. Histomorphometry of femurs from osteoclast/monocyte-lineage specific S1P 1 conditional knockout (S1PR1 2/2 ) mice, as well as mice ovariectomized/sham-operated and treated with FTY720 or vehicle, were performed using mCT. Assessment of osteoclast attachment to the bone surface was performed using a newly developed fully automated segmentation approach to analyse twophoton images of bone tissue sections in which osteoclasts and bone trabeculae were visualized with fluorescent TRAP staining 20 and second harmonic generation from collagen fibres 21 , respectively. To examine the composition of peripheral blood mononuclear cells (PMCs), the cells were stained with fluorophoreconjugated anti-F4/80, anti-CD11b and anti-CD3 using conventional methods. Flow cytometric data were collected on a FACSCalibur and analysed with FlowJo software. All mice were bred and maintained under specific pathogen-free conditions at the animal facility of the National Institutes of Health (NIH), according to NIH institutional guidelines under an approved protocol. For statistical analyses, the Mann-Whitney rank sum test was used to calculate P values for highly skewed distributions. For Gaussian-like distributions, two-tailed t-tests were used.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
METHODS
Cell culture. The RAW264.7 cell line and mouse BM-MDM cells, which contain osteoclast precursor cells, were cultured as previously described 28, 29 . To stimulate osteoclastogenesis, 50 ng ml 21 RANKL (PeproTech) was added to the medium and the cells were incubated for 3 to 4 days. Conventional and quantitative RT-PCR amplification. Conventional RT-PCR was performed as described previously 29 . Primers used are listed in Supplementary Table 4 . Relative quantification with real-time RT-PCR was performed using an ABI PRISM 7900 (Applied Biosystems Inc.) with an Assay-on Demand TaqMan probe and relevant primers, according to the manufacturer's instructions. Determination of Rac activity. Pulldown assay methods to determine the GTPbound active form of Rac have been described in detail previously 30 . In vitro chemotaxis chamber assay. Chemotactic migration of cells was measured in a modified Boyden chamber as described previously 27 . EZ-Taxiscan chemotaxis assay. Chemotaxis experiments were also conducted in an EZ-Taxiscan chamber according to the manufacturer's protocol (Effector Cell Institute). The EZ-Taxiscan is a visually-accessible chemotactic chamber, in which one compartment containing ligand (S1P) and another compartment containing cells are connected by a microchannel. Phase contrast images of migrating cells were acquired at 1 min intervals. Mice. C57BL/6 mice, CX 3 CR1-EGFP knock-in mice 12 , CSF1R (M-CSF receptor)-EGFP transgenic mice 14 , were obtained from The Jackson Laboratory. The generation of the loxP-flanked S1PR1 allele (S1PR1 loxP ) 18 and osteoclast/monocyte lineage-specific CD11b-Cre transgenic mice 19 were described previously. S1PR1 1/1 3 CD11b-Cre and S1PR1 loxP/1 3 CD11b-Cre littermates were born at expected frequencies and were viable and fertile, but live S1PR1 loxP/loxP 3 CD11b-Cre littermates were obtained rarely (three viable S1PR1 loxP/loxP 3 CD11b-Cre out of 59 total mice), suggesting possible embryonic lethality as seen with global S1P 1 deficiency. All mice were bred and maintained under specific pathogen-free conditions at animal facilities of NIH. Mutant mice were genotyped by PCR 18, 19 . All mice were housed and handled according to NIH institutional guidelines under an approved protocol. Immunohistochemistry. Immunohistological analyses were performed as described previously 2 . Anti-mouse S1P 1 rabbit polyclonal antibody was purchased from Affinity Bioreagents. In some experiments, fluorescence-based staining for TRAP 20 with ELF 97 substrate (Molecular Probes) was used with some modifications. Two-photon intravital bone tissue imaging. Intravital microscopy of mouse calvaria bone tissues was performed using a protocol modified from a previous report 10, 11 . Mice were anaesthetized with isoflurane (Baxter, 2.5% vaporized in an 80:20 mixture of oxygen and air), and the hair in the neck and scalp was removed with hair removal lotion (Nair). The frontoparietal skull was exposed and the mouse head was immobilized in a custom-made stereotactic holder. A catheter was placed into the tail vein with a 30-gauge needle attached to PE-10 tubing (Becton Dickinson). The imaging system was composed of an LSM510 NLO multiphoton microscope (Carl Zeiss) driven by a Chameleon XR Ti:Sapphire laser (Coherent) tuned to 880 nm, and an inverted microscope (Axiovert 200; Carl Zeiss) equipped with a 340 water immersion objective (Achroplan IR, NA 0.8; Carl Zeiss). Fluorescent cells were detected through a bandpass emission filter at 525/50 nm (for EGFP). Vessels were visualized by injecting 70 kDa Texas Red conjugated-dextran (detected using a 620/60 nm filter) intravenously immediately before imaging. Image stacks were collected at 3-mm vertical step size at a depth of 100-150 mm below the skull bone surface. For three-dimensional videos, four sequential image stacks were acquired at 3 mm z spacing to cover a volume of 154 3 154 3 9.0 mm. The time resolution was 1 min. Raw imaging data were processed with Imaris (Bitplane) with a Gaussian filter for noise reduction. Ovariectomy and FTY720 treatment. Twelve 12-week-old female, ovariectomized or sham-operated, C57BL/6J mice were purchased from Charles River Laboratories. Mice were injected intraperitoneally either with FTY720 (3 mg kg 21 , Cayman Chemical) dissolved in a vehicle (PBS containing 5% acidified DMSO and 30% fatty acid-free BSA) or with vehicle only, daily for 4 weeks. The mice were then killed and femurs were excised and fixed. Uteri of all the animals were excised and were weighed to evaluate the effect of ovariectomy. Bone histomorphometry. Trabecular bone morphometry within the metaphyseal region of distal femur was quantified using micro-CT (mCT40, Scanco Medical AG). Volumeric regions for trabecular analysis were selected within the endosteal borders to include the central 80% of vertebral height and secondary spongiosa of femoral metaphyses located ,6% of the total length from the growth plate. Trabecular morphometry was characterized by measuring the bone volume fraction (bone volume/total volume), trabecular thickness and trabecular number. To assess the attachment of osteoclasts to the bone surface, osteoclasts and bone trabeculae were fluorescently visualized in sections by two-photon microscopy. To identify osteoclasts, fluorescence based TRAP staining 20 was performed. Collagen-enriched bone matrices could be visualized using the second harmonic emission from collagen fibres excited by infrared lasers. Sections were examined using a two-photon laser microscope (laser was tuned to 780 nm). Fluorescence was detected through bandpass emission filters at 370-450 nm (for second harmonic emission from bone matrices) or 525/50 nm (for TRAP staining). Image analysis was performed using a fully automated segmentation approach (no manual tracing of cell/tissue boundaries or other user intervention required) and the 'osteoclast attachment ratio' was calculated as the ratio 'bone surface attached by osteoclasts/total bone surface' (F.K., submitted manuscript). Flow cytometry. All reagents were purchased from BD PharMingen. To examine the composition of PMCs, blood was collected from the retro-orbital plexus with a heparinized glass pipette, from mice treated intraperitoneally 4 h previously with FTY720 (3 mg kg 21 ) or vehicle (Fig. 4) , or treated intravenously 1 h previously with SEW2871 (5 mg kg
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) or vehicle ( Supplementary Fig. 4 ). After removing the red blood cells using ACK lysis buffer (Invitrogen), cells were stained with Alexa647-conjugated anti-F4/80 (Fig. 4) , or FITC-conjugated anti-CD11b and PE-Cy7-conjugated anti-CD3 (Supplementary Figs 4 and 9) , using conventional methods. Flow cytometric data were collected on a FACSCalibur (Becton Dickinson) and analysed with FlowJo software (TreeStar).
